Skip to content

Study · Animal study (in vivo) · mouse · 2018

7 results

Chronic linaclotide treatment reduces colitis-induced neuroplasticity and reverses persistent bladder dysfunction.

Grundy L, Harrington AM, Castro J, Garcia-Caraballo S, Deiteren A, Maddern J, Rychkov GY, Ge P, Peters S, Feil R, Miller P, Ghetti A and 4 more

Show all authors

Hannig G, Kurtz CB, Silos-Santiago I, Brierley SM

JCI insight4 Oct 2018Cited by 68 (Europe PMC)

PMID30282832 (opens in a new tab)PMCIDPMC6237488 (opens in a new tab)DOI10.1172/jci.insight.121841 (opens in a new tab)PepBankPUB-30282832
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, daily linaclotide reversed colonic afferent hypersensitivity.

    In plain wordsIn mice, daily linaclotide reversed colonic afferent hypersensitivity.

    Peptide
    Linaclotide
    Outcome
    DecreaseColonic afferent hypersensitivity
    Study

    mousen: not reported in source

    colitis-associated persistent visceral hypersensitivity
    Outcome group
    Pain · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Daily administration of linaclotide, a guanylate cyclase-C (GC-C) agonist that is restricted to and acts within the gastrointestinal tract, reverses colonic afferent hypersensitivity, reverses neuroplasticity-induced alterations in spinal circuitry, and alleviates chronic abdominal pain in mice.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In mice, daily linaclotide reversed neuroplasticity-induced alterations in spinal circuitry.

    In plain wordsIn mice, daily linaclotide reversed changes in spinal circuitry.

    Peptide
    Linaclotide
    Outcome
    DecreaseSpinal circuitry alterations
    Study

    mousen: not reported in source

    colitis-associated persistent visceral hypersensitivity
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Daily administration of linaclotide, a guanylate cyclase-C (GC-C) agonist that is restricted to and acts within the gastrointestinal tract, reverses colonic afferent hypersensitivity, reverses neuroplasticity-induced alterations in spinal circuitry, and alleviates chronic abdominal pain in mice.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice, daily linaclotide alleviated chronic abdominal pain.

    In plain wordsIn mice, daily linaclotide reduced chronic abdominal pain.

    Peptide
    Linaclotide
    Outcome
    DecreaseChronic abdominal pain
    Study

    mousen: not reported in source

    colitis-associated persistent visceral hypersensitivity
    Outcome group
    Pain · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Daily administration of linaclotide, a guanylate cyclase-C (GC-C) agonist that is restricted to and acts within the gastrointestinal tract, reverses colonic afferent hypersensitivity, reverses neuroplasticity-induced alterations in spinal circuitry, and alleviates chronic abdominal pain in mice.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice, daily linaclotide reversed persistent bladder afferent hypersensitivity to mechanical stimuli.

    In plain wordsIn mice, daily linaclotide reduced bladder nerve hypersensitivity to mechanical stimuli.

    Peptide
    Linaclotide
    Outcome
    DecreaseMechanical bladder afferent hypersensitivity
    Study

    mousen: not reported in source

    colitis-associated persistent visceral hypersensitivity
    Outcome group
    Pain · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Intriguingly, daily linaclotide administration also reverses persistent bladder afferent hypersensitivity to mechanical and chemical stimuli and restores normal bladder voiding.
    1 context sentence
    Summary · context
    Daily administration of linaclotide, a guanylate cyclase-C (GC-C) agonist that is restricted to and acts within the gastrointestinal tract, reverses colonic afferent hypersensitivity, reverses neuroplasticity-induced alterations in spinal circuitry, and alleviates chronic abdominal pain in mice.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice, daily linaclotide reversed persistent bladder afferent hypersensitivity to chemical stimuli.

    In plain wordsIn mice, daily linaclotide reduced bladder nerve hypersensitivity to chemical stimuli.

    Peptide
    Linaclotide
    Outcome
    DecreaseChemical bladder afferent hypersensitivity
    Study

    mousen: not reported in source

    colitis-associated persistent visceral hypersensitivity
    Outcome group
    Pain · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Intriguingly, daily linaclotide administration also reverses persistent bladder afferent hypersensitivity to mechanical and chemical stimuli and restores normal bladder voiding.
    1 context sentence
    Summary · context
    Daily administration of linaclotide, a guanylate cyclase-C (GC-C) agonist that is restricted to and acts within the gastrointestinal tract, reverses colonic afferent hypersensitivity, reverses neuroplasticity-induced alterations in spinal circuitry, and alleviates chronic abdominal pain in mice.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In mice, daily linaclotide restored normal bladder voiding.

    In plain wordsIn mice, daily linaclotide restored normal bladder voiding.

    Peptide
    Linaclotide
    Outcome
    Not applicableBladder voiding
    Study

    mousen: not reported in source

    colitis-associated persistent visceral hypersensitivity
    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Intriguingly, daily linaclotide administration also reverses persistent bladder afferent hypersensitivity to mechanical and chemical stimuli and restores normal bladder voiding.
    1 context sentence
    Summary · context
    Daily administration of linaclotide, a guanylate cyclase-C (GC-C) agonist that is restricted to and acts within the gastrointestinal tract, reverses colonic afferent hypersensitivity, reverses neuroplasticity-induced alterations in spinal circuitry, and alleviates chronic abdominal pain in mice.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In mice, linaclotide did not directly inhibit bladder afferents. Bladder normalization involved reduced nociceptive signaling from the colon.

    In plain wordsIn mice, linaclotide did not directly inhibit bladder nerves. Its effect involved reduced pain signaling from the colon.

    Peptide
    Linaclotide
    Outcome
    Direction not reportedDirect bladder afferent inhibition
    Study

    mousen: not reported in source

    colitis-associated persistent visceral hypersensitivity
    Outcome group
    Receptor activity and mechanism · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Linaclotide itself does not inhibit bladder afferents, rather normalization of bladder function by daily linaclotide treatment occurs via indirect inhibition of bladder afferents via reduced nociceptive signaling from the colon.
    1 context sentence
    Summary · context
    Daily administration of linaclotide, a guanylate cyclase-C (GC-C) agonist that is restricted to and acts within the gastrointestinal tract, reverses colonic afferent hypersensitivity, reverses neuroplasticity-induced alterations in spinal circuitry, and alleviates chronic abdominal pain in mice.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.